EPZM Projected Dividend Yield

Epizyme Inc. ( NASDAQ : EPZM )

Epizyme is a biopharmaceutical company that is focused on rewriting treatment for people with cancer and other serious diseases through the discovery, development, and commercialization of epigenetic medicines. Co. has one approved product, TAZVERIK (tazemetostat), which was granted approval by the U.S. Food and Drug Administration (FDA) for epithelioid sarcoma (ES), and follicular lymphoma (FL). The FDA has granted approval of TAZVERIK (tazemetostat), an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection.

20 YEAR PERFORMANCE RESULTS